TIMP1 inhibits Rac1-mediated ROS production to ameliorate blood–spinal cord barrier disruption in amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the progressive degeneration of motor neurons, for which therapeutic strategies and pharmacological interventions remain limited. Disruption of the blood–spinal cord barrier (BSCB) has been identified as a significa...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingshu Tang, Yuying Kang, Qiuyu Chen, Baodan Zhang, Nianying Shang, Jiaqi Lan, Lei Wu, Ying Peng
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Neurobiology of Disease
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996125002037
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849418679655071744
author Jingshu Tang
Yuying Kang
Qiuyu Chen
Baodan Zhang
Nianying Shang
Jiaqi Lan
Lei Wu
Ying Peng
author_facet Jingshu Tang
Yuying Kang
Qiuyu Chen
Baodan Zhang
Nianying Shang
Jiaqi Lan
Lei Wu
Ying Peng
author_sort Jingshu Tang
collection DOAJ
description Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the progressive degeneration of motor neurons, for which therapeutic strategies and pharmacological interventions remain limited. Disruption of the blood–spinal cord barrier (BSCB) has been identified as a significant factor that may exacerbate motor neuron damage. Tissue inhibitor of metalloproteinase-1 (TIMP1), a molecule known for its dual roles in inhibiting matrix metalloproteinase (MMP) activity and exerting cytokine-like effects via receptor interactions, has been demonstrated to ameliorate endothelial barrier damage in various diseases. Here, we explored the potential of TIMP1 to restore BSCB integrity as a strategy to slow the ALS progression. Specifically, the expression of TIMP1 or its mutant variant AlaTIMP1, which lacks MMP-inhibitory activity, in spinal cord microvascular endothelial cells (SCMECs) prior to disease onset significantly reduces BSCB leakage in mice with ALS, thereby alleviating motor function deficits and delaying disease progression. Additionally, TIMP1 expression restores the expression of junctional complexes in SCMECs, as demonstrated in both in vivo and in vitro ALS models. Mechanistic studies revealed that TIMP1 suppresses ALS injury-induced integrin β1 activation independent of MMP inhibition, blocking downstream Rac1 translocation to the membrane to form a complex with NOX2. The inhibition of NOX2 activity reduces ROS-induced cytoskeletal remodeling, consequently stabilizing overall junctional alignment and preserving the BSCB integrity. Overall, our findings elucidate an MMP-independent mechanism through which TIMP1 regulates BSCB integrity in ALS context, suggesting that TIMP1 could serve as a novel tool for the treatment of ALS, particularly for prophylactic treatment in patients with familial ALS.
format Article
id doaj-art-2fbc6845adcf4a67b5b0925cdfca9a33
institution Kabale University
issn 1095-953X
language English
publishDate 2025-09-01
publisher Elsevier
record_format Article
series Neurobiology of Disease
spelling doaj-art-2fbc6845adcf4a67b5b0925cdfca9a332025-08-20T03:32:23ZengElsevierNeurobiology of Disease1095-953X2025-09-0121310698710.1016/j.nbd.2025.106987TIMP1 inhibits Rac1-mediated ROS production to ameliorate blood–spinal cord barrier disruption in amyotrophic lateral sclerosisJingshu Tang0Yuying Kang1Qiuyu Chen2Baodan Zhang3Nianying Shang4Jiaqi Lan5Lei Wu6Ying Peng7State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, ChinaState Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, ChinaCorresponding author at: Pharmacology Department, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1, Xiannongtan Street, Xicheng District, Beijing 100050, China.; State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, ChinaAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the progressive degeneration of motor neurons, for which therapeutic strategies and pharmacological interventions remain limited. Disruption of the blood–spinal cord barrier (BSCB) has been identified as a significant factor that may exacerbate motor neuron damage. Tissue inhibitor of metalloproteinase-1 (TIMP1), a molecule known for its dual roles in inhibiting matrix metalloproteinase (MMP) activity and exerting cytokine-like effects via receptor interactions, has been demonstrated to ameliorate endothelial barrier damage in various diseases. Here, we explored the potential of TIMP1 to restore BSCB integrity as a strategy to slow the ALS progression. Specifically, the expression of TIMP1 or its mutant variant AlaTIMP1, which lacks MMP-inhibitory activity, in spinal cord microvascular endothelial cells (SCMECs) prior to disease onset significantly reduces BSCB leakage in mice with ALS, thereby alleviating motor function deficits and delaying disease progression. Additionally, TIMP1 expression restores the expression of junctional complexes in SCMECs, as demonstrated in both in vivo and in vitro ALS models. Mechanistic studies revealed that TIMP1 suppresses ALS injury-induced integrin β1 activation independent of MMP inhibition, blocking downstream Rac1 translocation to the membrane to form a complex with NOX2. The inhibition of NOX2 activity reduces ROS-induced cytoskeletal remodeling, consequently stabilizing overall junctional alignment and preserving the BSCB integrity. Overall, our findings elucidate an MMP-independent mechanism through which TIMP1 regulates BSCB integrity in ALS context, suggesting that TIMP1 could serve as a novel tool for the treatment of ALS, particularly for prophylactic treatment in patients with familial ALS.http://www.sciencedirect.com/science/article/pii/S0969996125002037Amyotrophic lateral sclerosisTissue inhibitor of metalloproteinase-1Blood–spinal cord barrierTight junction complexesReactive oxygen speciesCytoskeleton
spellingShingle Jingshu Tang
Yuying Kang
Qiuyu Chen
Baodan Zhang
Nianying Shang
Jiaqi Lan
Lei Wu
Ying Peng
TIMP1 inhibits Rac1-mediated ROS production to ameliorate blood–spinal cord barrier disruption in amyotrophic lateral sclerosis
Neurobiology of Disease
Amyotrophic lateral sclerosis
Tissue inhibitor of metalloproteinase-1
Blood–spinal cord barrier
Tight junction complexes
Reactive oxygen species
Cytoskeleton
title TIMP1 inhibits Rac1-mediated ROS production to ameliorate blood–spinal cord barrier disruption in amyotrophic lateral sclerosis
title_full TIMP1 inhibits Rac1-mediated ROS production to ameliorate blood–spinal cord barrier disruption in amyotrophic lateral sclerosis
title_fullStr TIMP1 inhibits Rac1-mediated ROS production to ameliorate blood–spinal cord barrier disruption in amyotrophic lateral sclerosis
title_full_unstemmed TIMP1 inhibits Rac1-mediated ROS production to ameliorate blood–spinal cord barrier disruption in amyotrophic lateral sclerosis
title_short TIMP1 inhibits Rac1-mediated ROS production to ameliorate blood–spinal cord barrier disruption in amyotrophic lateral sclerosis
title_sort timp1 inhibits rac1 mediated ros production to ameliorate blood spinal cord barrier disruption in amyotrophic lateral sclerosis
topic Amyotrophic lateral sclerosis
Tissue inhibitor of metalloproteinase-1
Blood–spinal cord barrier
Tight junction complexes
Reactive oxygen species
Cytoskeleton
url http://www.sciencedirect.com/science/article/pii/S0969996125002037
work_keys_str_mv AT jingshutang timp1inhibitsrac1mediatedrosproductiontoamelioratebloodspinalcordbarrierdisruptioninamyotrophiclateralsclerosis
AT yuyingkang timp1inhibitsrac1mediatedrosproductiontoamelioratebloodspinalcordbarrierdisruptioninamyotrophiclateralsclerosis
AT qiuyuchen timp1inhibitsrac1mediatedrosproductiontoamelioratebloodspinalcordbarrierdisruptioninamyotrophiclateralsclerosis
AT baodanzhang timp1inhibitsrac1mediatedrosproductiontoamelioratebloodspinalcordbarrierdisruptioninamyotrophiclateralsclerosis
AT nianyingshang timp1inhibitsrac1mediatedrosproductiontoamelioratebloodspinalcordbarrierdisruptioninamyotrophiclateralsclerosis
AT jiaqilan timp1inhibitsrac1mediatedrosproductiontoamelioratebloodspinalcordbarrierdisruptioninamyotrophiclateralsclerosis
AT leiwu timp1inhibitsrac1mediatedrosproductiontoamelioratebloodspinalcordbarrierdisruptioninamyotrophiclateralsclerosis
AT yingpeng timp1inhibitsrac1mediatedrosproductiontoamelioratebloodspinalcordbarrierdisruptioninamyotrophiclateralsclerosis